Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stemline Therapeutics, Inc.

https://stemline.com/

Latest From Stemline Therapeutics, Inc.

EMA To Revisit Rejection Of Elzonris & Gamifant

A much slimmed-down August agenda for the European Medicines Agency’s drug assessment body, the CHMP, also shows that Janssen has asked for more time to reply to questions about its potential multiple sclerosis therapy, ponesimod.

Europe Regulation

Menarini Expands In Cancer With Radius Drug Deal

Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.

Cancer Deals

Sobi To Appeal Against EMA Rejection For Emapalumab

The company says its drug has demonstrated a positive benefit-risk profile in primary HLH in a post-approval real-life setting in the US since Food and Drug Administration approval in 2018.

Drug Review Europe

EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab

GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.

Europe Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register